SK Bioscience Enters Clinical Trials for Universal Vaccine to Combat COVID-19 and Future Coronavirus Strains

Strategic Insights -

As the world continues to grapple with the COVID-19 pandemic, SK Bioscience is taking a pioneering step towards developing a universal vaccine that can combat various coronavirus strains, including COVID-19 and SARS. The company has submitted a global Phase 1/2 clinical trial plan for its vaccine candidate 'GBP511' to the Australian Human Research Ethics Committee (HREC), targeting the 'sarbecovirus' family.

GBP511 utilizes the foundational technology of 'SKYCovione,' the only COVID-19 vaccine in Korea that SK Bioscience successfully commercialized in 2022, and the 'Self Assembly Nanoparticle' design technology from the Institute for Protein Design (IPD) at the University of Washington School of Pharmacy. The vaccine is expected to be effective against a wide range of viruses, including COVID-19, SARS, and variant strains.

Key Takeaways:

  • SK Bioscience has submitted a global Phase 1/2 clinical trial plan for its vaccine candidate 'GBP511' to the Australian Human Research Ethics Committee (HREC).
  • GBP511 is expected to be effective against a wide range of viruses, including COVID-19, SARS, and variant strains.
  • The vaccine leverages the underlying technology of SK Bioscience's Skycobi-one, Korea's only COVID-19 vaccine successfully commercialized in 2022.
  • SK Bioscience plans to further strengthen its portfolio for responding to global health crises through the development of various vaccines.
  • The Phase 1/2 clinical trial will target approximately 500 Australian adults aged 18 and over, with key findings expected by 2028.
  • The vaccine development project was launched in 2021 in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) and received approximately $65 million in initial research and development costs.
  • GBP511 was developed based on SK Bioscience's genetic recombination technology and the "Self-Assembly Nanoparticle" design technology from the Institute for Protein Design (IPD) at the University of Washington's School of Pharmacy.

Statistics:

  • The global COVID-19 vaccine market is estimated to be worth approximately $50.6 billion in 2025 (Source: Coherent Market Insights).
  • The market is projected to grow at a compound annual growth rate of 7.4% from 2025 to 2032, reaching approximately $83.4 billion by 2032 (Source: Coherent Market Insights).
  • The World Health Organization (WHO) designated the development of a universal vaccine capable of responding to various sarbecoviruses as a top global health priority in its January 2022 report (Source: WHO).

Sources:

  • SK Bioscience
  • Australian Human Research Ethics Committee (HREC)
  • Institute for Protein Design (IPD) at the University of Washington School of Pharmacy
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • Coherent Market Insights
  • World Health Organization (WHO)